Abstract Recent studies suggested that ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor, developed for the treatment of chronic lymphocytic leukemia, may prevent NLRP3 inflammasome activation in macrophages, IL-1β secretion and subsequent development of inflammation and organ fibrosis. The role of NLRP3 has been underlined in the various causes of acute kidney injury (AKI), a pathology characterized by high morbimortality and risk of transition toward chronic kidney disease (CKD). We therefore hypothesized that the BTK-inhibitor ibrutinib could be a candidate drug for AKI treatment. Here, we observed in both an AKI model (glycerol-induced rhabdomyolysis) and a model of rapidly progressive kidney fibrosis (unilateral ureteral obstruction)...
Ibrutinib has potential therapeutic or protective effects against viral- and bacterial-induced acute...
Background and Purpose: There are no medications currently available to treat metabolic inflammation...
Aim: The Bruton's tyrosine kinase (BTK) inhibitor Ibrutinib (PCI-32765) is effective in patients wit...
International audienceBackground: Acute kidney injury (AKI) is a major risk factor for the developme...
Background: Acute kidney injury (AKI) is a major risk factor for the development of chronic kidney d...
Background and Purpose Currently there are limited medicines available for the treatment of metaboli...
Hemolytic-uremic syndrome (HUS) can occur as a complication of an infection with Shiga-toxin (Stx)-p...
BACKGROUND: Acute kidney injury (AKI) is a major risk factor for the development of chronic kidney d...
This is an open-access article distributed under the terms of the Creative Commons Attribution Licen...
Hemolytic-uremic syndrome (HUS) can occur as a complication of an infection with Shiga-toxin (Stx)-p...
The activation of the B cell receptor (BCR) is nowadays known to play a primary role in the etiopath...
Bruton’s tyrosine kinase (BTK) is a cytoplasmic protein found in all hematopoietic cell lineages exc...
The activation of the B cell receptor (BCR) is nowadays known to play a primary role in the etiopath...
Ibrutinib is a tyrosine kinase inhibitor used in the treatment of a variety of lymphoid malignancies...
PubMedID: 30878129Bruton tyrosine kinase signaling (BTK) is critical step for B-cell development and...
Ibrutinib has potential therapeutic or protective effects against viral- and bacterial-induced acute...
Background and Purpose: There are no medications currently available to treat metabolic inflammation...
Aim: The Bruton's tyrosine kinase (BTK) inhibitor Ibrutinib (PCI-32765) is effective in patients wit...
International audienceBackground: Acute kidney injury (AKI) is a major risk factor for the developme...
Background: Acute kidney injury (AKI) is a major risk factor for the development of chronic kidney d...
Background and Purpose Currently there are limited medicines available for the treatment of metaboli...
Hemolytic-uremic syndrome (HUS) can occur as a complication of an infection with Shiga-toxin (Stx)-p...
BACKGROUND: Acute kidney injury (AKI) is a major risk factor for the development of chronic kidney d...
This is an open-access article distributed under the terms of the Creative Commons Attribution Licen...
Hemolytic-uremic syndrome (HUS) can occur as a complication of an infection with Shiga-toxin (Stx)-p...
The activation of the B cell receptor (BCR) is nowadays known to play a primary role in the etiopath...
Bruton’s tyrosine kinase (BTK) is a cytoplasmic protein found in all hematopoietic cell lineages exc...
The activation of the B cell receptor (BCR) is nowadays known to play a primary role in the etiopath...
Ibrutinib is a tyrosine kinase inhibitor used in the treatment of a variety of lymphoid malignancies...
PubMedID: 30878129Bruton tyrosine kinase signaling (BTK) is critical step for B-cell development and...
Ibrutinib has potential therapeutic or protective effects against viral- and bacterial-induced acute...
Background and Purpose: There are no medications currently available to treat metabolic inflammation...
Aim: The Bruton's tyrosine kinase (BTK) inhibitor Ibrutinib (PCI-32765) is effective in patients wit...